Aafiya combines a clinically validated AI engine with HPCSA-registered physicians to deliver signed consultation notes and e-prescriptions. The platform is substantially built — microservice architecture, multi-language support and full clinical workflow. Now raising to validate and commercialise.
Aafiya is developed with input from leading healthcare professionals, regulatory experts, and technology partners.
Every consultation signed by registered physicians
SA data protection compliance, Johannesburg hosting
Designed for Medical Device Act compliance
FHIR R4 standard, ready for Fund accreditation
Seeking HPCSA-registered physicians with expertise in primary care, public health, HIV/TB medicine, and chronic disease management to guide clinical protocols and validation studies.
Partnering with regulatory experts in SAHPRA compliance, Medical Schemes Act, and National Health Insurance regulations to ensure full legal and ethical compliance.
The public health system has lost more than 12,745 doctors and 58,897 nurses since 2013. Over 80% of doctors serve just 15% of the population. The gap is accelerating.
0.31 doctors per 1,000 people vs. the WHO minimum of 1.0. Over 23,400 SA health professionals now work abroad in the UK, USA, Australia and New Zealand.
World's largest HIV burden (7.8M people). 6th highest TB rate globally. Rapidly growing hypertension and diabetes epidemic. Non-SA AI models are not trained on this syndemic.
Only 15% of the population (9M people) hold medical aid. 50M+ South Africans rely on an overwhelmed public sector with no digital primary care alternative.
Aafiya is not telemedicine. It is a physician-supervised AI care delivery system purpose-built for South Africa's disease burden, languages, and regulatory requirements.
Two-stage safety screen in under 500ms. Deterministic emergency rules engine + LLM classifier. Routes EMERGENCY cases to 112/10177 before clinical intake begins.
Structured clinical assessment in all 11 SA official languages, including image upload for dermatology and wounds. Fine-tuned on SA disease patterns: HIV/TB, NCDs, and EML.
Every AI output is reviewed by an HPCSA-registered physician before it reaches the patient. No AI diagnosis is ever delivered autonomously. Review averages 3–8 minutes.
Signed consultation note and e-prescription via WhatsApp or SMS — E-prescriptions route to Dis-Chem, Clicks, and independent pharmacy networks.
The timing to build and scale Aafiya has never been better — and the window is closing.
The National Health Insurance Act establishes a single-purchaser primary care system targeting 50M beneficiaries. Aafiya is architected to be NHI accredited by 2027–2030.
SAHPRA's Call-Up Notices for AI clinical decision support have not yet been issued (as of 2026). First movers who validate and register now will have a durable regulatory head-start.
67 telemedicine startups operate in South Africa, but none combine AI-assisted intake, mandatory physician sign-off and NHI-ready data architecture.
The platform is substantially complete. Fourteen major capabilities delivered across three development waves. The investable question is no longer whether the software can be built — it is built. It’s whether Aafiya can convert a built platform into validated, reimbursable, regulated care delivery.
Two-stage pipeline under 500ms: 13 deterministic emergency rules + LLM classifier. EMERGENCY, URGENT, ROUTINE, and SELF_CARE outcomes. Auto-generates the SAHPRA regulatory evidence file.
Full CDM module for hypertension, diabetes, HIV, and TB. Automated recall scheduling, medication adherence tracking, and integrated care plans covering 12M+ SA patients.
Image upload directly in clinical intake for dermatology, wounds, and eye conditions. Physicians review images alongside AI assessment — no separate dermatology referral needed.
Consultation results, e-prescriptions, and appointment reminders delivered via WhatsApp in 4 languages. SMS fallback for low-bandwidth and feature phones.
FHIR R4 lab integration framework with abnormal flag detection. Physicians see results in the same case view — no manual re-entry, no fax. Partner adapters (PathCare, Ampath) in progress.
CGM device integration (Dexcom CLARITY, FreeStyle Libre) operational. Apple HealthKit and Android Health Connect adapters planned. Glucose data flows into CDM care plans.
TB-specific triage pathway with chest X-ray AI analysis and GeneXpert integration — targeting South Africa's world-high TB burden in the communities that need it most.
Clinical intake, triage, consent flows, and SMS prescriptions in all 11 SA languages. Speech-to-text in every language. Aafiya now addresses the entire SA population.
Points ledger with fraud caps, BRONZE→DIAMOND tier engine, redemption catalogue, nightly GEMS reporting, and Prometheus-alerted fraud queue. Fully integrated with POPIA consent framework.
Multi-gateway routing via Ozow (EFT) and PayFast (card/EFT). SASSA-subsidised tier at R50. 24-hour auto-refund for cancelled consultations.
Bidirectional referrals to GoodX (REST) and Elixir (HL7 MLLP) practice management systems. Retry engine with exponential back-off and webhook status callbacks.
Real-time SA ID verification against the Department of Home Affairs NPR at registration. SASSA grant-holder co-verification. Manual admin override with audit trail during DHA downtime.
Dexcom CLARITY and Abbott FreeStyle Libre continuous glucose monitoring stored as FHIR Observations with physician-configurable alert thresholds.
Aafiya's five-layer architecture handles the full clinical workflow — from patient intake to pharmacy delivery — on SA-resident cloud infrastructure (POPIA-compliant).
Track Aafiya's progress toward clinical validation, regulatory approval, and commercial launch.
SA clinical corpus fine-tuning, SAHPRA pre-submission, physician recruitment
3 pilot sites, ≥1,500 consultations, SAHPRA technical evidence file, ≥30 physicians
≥1 scheme partner live, ≥8,000 consultations, first revenue, Series A preparation
Multi-scheme scale, SAHPRA registration, ISO 13485, Series A
The platform is substantially built. Aafiya is raising R12–18M to complete clinical validation, SAHPRA engagement, physician onboarding, and first scheme partnership — the 9–12 month path to Series A readiness.